Tvardi Therapeutics
TVRD
127 hedge funds and large institutions have $307M invested in Tvardi Therapeutics in 2017 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 46 increasing their positions, 34 reducing their positions, and 17 closing their positions.
82% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 17
35% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 34
11% more funds holding
Funds holding: 114 → 127 (+13)
4% more capital invested
Capital invested by funds: $296M → $307M (+$10.4M)
0.01% less ownership
Funds ownership: 1.72% → 1.7% (-0.01%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
43% less call options, than puts
Call options by funds: $20.6M | Put options by funds: $36.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$49.9M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.25M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.58M |
| 4 |
BlackRock
New York
|
+$4.14M |
| 5 |
Morgan Stanley
New York
|
+$3.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$17.6M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$7.08M |
| 3 |
Jennison Associates
New York
|
-$5.52M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$2.78M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$2.76M |
TVRD Hedge Fund Activity: Q2 2017 in Review
127 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q2 2017, worth a combined $307M — up 3.5% from $296M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new TVRD positions and 17 closed out — a net gain of 14 holders — while 46 added to existing stakes and 34 trimmed.
The largest buyer was State Street, adding an estimated $49.9M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $17.6M sold.
- 127 institutional investors held Tvardi Therapeutics (TVRD) as of Q2 2017, up from 114 in Q1 2017.
- Funds reported $307M of Tvardi Therapeutics stock for Q2 2017, up 3.5% quarter-over-quarter.
- 31 funds opened new Tvardi Therapeutics positions in Q2 2017 and 17 closed out, a net change of +14 holders.
- The largest Tvardi Therapeutics buyer in Q2 2017 was State Street, an estimated $49.9M added.
- The largest Tvardi Therapeutics seller in Q2 2017 was Susquehanna International Group, an estimated $17.6M sold.
Based on aggregated 13F filings for Q2 2017.